Chris Verslype explains that the management of gastroenteropancreatic neuroendocrine neoplasms (GEP NENs) should rely on pathology findings on how well differentiated the tumour is, and the level of proliferation marker Ki67. He describes treatment options and follow-up plan recommendations according to disease staging.
This video was supported with an unrestricted grant from IPSEN. The selection of questions covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.